I Europa varierer bedømmelsen af effekt hos børn under 2 år fra 51% til 79%, når vaccinedækningen mod serotyper, der forårsager invasiv sygdom, tages i betragtning.
In Europe, the estimates of effectiveness in children less than 2 years of age range from 51% to 79% when considering vaccine coverage against serotypes causing invasive disease.